Bharat Serums and Vaccines invests Rs 200 Cr in new biopharmaceutical manufacturing plant in Genome Valley

Xin Weisheng

Home > News > INDUSTRY NEWS >

27 Sep 2023
Bharat Serums and Vaccines invests Rs 200 Cr in new biopharmaceutical manufacturing plant in Genome Valley

Bharat Serums and Vaccines Limited (BSV) hosted the groundbreaking ceremony of its new manufacturing plant at Genome Valley in Hyderabad, Telangana, in the presence of K.T Rama Rao, Minister for Municipal Administration and Urban Development; Industries and Commerce; and Information Technology, Electronics and Communications of Telangana.


BSV currently has a manufacturing facility in Ambernath, Maharashtra that caters to domestic and more than 80 export markets and a manufacturing facility in Aachen, Germany, that serves the international markets.


The new manufacturing facility in Genome Valley will cover an area of 10 acres and involve an investment of Rs 200 crore.  It aims to provide long-term employment opportunities to the people of the Telangana State as well as upskilling of capabilities.


With this manufacturing facility, BSV aims to significantly increase its capacity in producing injectables with the commissioning of the fill-finish formulation line in phase 1 and an additional multi-product line in phase 2 of the project. The manufacturing facility endeavors to produce world-class products that adhere to International Quality Systems while complying to the Indian regulatory norms of Schedule M as well as the Global regulatory requirements in the world. The facility will produce women health products, rabies vaccines, immunoglobulins, hormones, among others.


(Source: BioSpectrum)

  • wechat
Recent Posts
  • Radiopharma-Focused CDMO Nucleus Unveils Two New Plants, Looks to Create 100 Jobs
    22 Oct 2024
    Radiopharma-Focused CDMO Nucleus Unveils Two New Plants, Looks to Create 100 Jobs
    Find out more
  • Just – Evotec Biologics Opens Its First J.POD Facility in Europe
    20 Sep 2024
    Just – Evotec Biologics Opens Its First J.POD Facility in Europe
    Find out more
  • AI biotechs Exscientia and Recursion agree $688m merger
    12 Aug 2024
    AI biotechs Exscientia and Recursion agree $688m merger
    Find out more

WANT TO KNOW MORE ABOUT HOW OUR

SOLUTIONS CAN HELP YOU?

Cookies
Our site uses cookies. We’d also like to set optional cookies to give you the best experience and porvide you relevant advertising. You can choose to manage your preferences or accept all cookies. You can also read our Privacy Policy and Cookie Policy for more information.